Lineage Cell Therapeutics (LCTX) Total Liabilities (2010 - 2026)

Lineage Cell Therapeutics' Total Liabilities history runs 17 years deep, the most recent figure standing at $56.8 million for Q1 2026.

• On a quarterly basis, Total Liabilities rose 66.69% year-over-year to $56.8 million in Q1 2026; TTM through Mar 2026 was $56.8 million, a 66.69% increase from a year earlier, with the FY2025 full-year figure at $69.2 million, up 91.23% from the prior year.
• Total Liabilities retreated to $56.8 million in Q1 2026 per LCTX's latest filing, from $69.2 million in the prior quarter.
• Across five years, Total Liabilities topped out at $69.2 million in Q4 2025 and bottomed at $31.8 million in Q3 2024.
• The 5-year median for Total Liabilities is $43.7 million (2025), against an average of $46.8 million.
• Biggest YoY gain for Total Liabilities was 422.12% in 2022; the steepest drop was 38.16% in 2022.
• Year by year, Total Liabilities stood at $51.7 million in 2022, then slipped by 24.61% to $39.0 million in 2023, then retreated by 7.15% to $36.2 million in 2024, then soared by 91.23% to $69.2 million in 2025, then slipped by 17.91% to $56.8 million in 2026.
• Per Business Quant, the three latest LCTX Total Liabilities figures stand at $56.8 million (Q1 2026), $69.2 million (Q4 2025), and $68.8 million (Q3 2025).